
Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history: Sun Pharma’s agreement to acquire Organon in an all-cash deal that values the company at $11.75 billion. Organon shareholders approved the deal on July 23, 2026 and closing is expected in early 2027.
Organon is a global leader in women’s health, with more than 70 products across women’s health and general medicines sold in 140 countries. Since spinning out of Merck in 2021, Organon has built trust with clinicians, patients and regulators across geographies.
Organon’s products serve women throughout their reproductive years and capture massive markets. In contraception, Nexplanon is a matchstick-sized implant placed in the upper arm that provides highly effective birth control without a daily pill. In vaginal health, Xaciato is a single-dose gel for bacterial vaginosis, the most common vaginal infection in women of reproductive age. In fertility, Follistim AQ stimulates egg development during IVF, while Ganirelix Acetate Injection prevents premature ovulation so clinicians can time egg retrieval precisely. Each one serves a need millions of women face, and across the full portfolio, Organon brought in $6.2 billion in revenue in 2025.

For Sun Pharma, India’s largest drugmaker, the deal is a way into women’s health at scale. After closing, Sun expects to rank among the top three women’s health companies globally. Sun Pharma’s Managing Director, Kirti Ganorkar, said the combined company wants to be a partner of choice for acquiring and launching new products, which is good news for founders building in this space.
This transaction signals that strategic buyers consider women’s health a core growth engine. Though strategic buyers are not the only ones placing that bet. Last October, Blackstone and TPG agreed to take Hologic, another global leader in women’s health, private for up to $18.3 billion. Within roughly six months, two very different kinds of capital, private equity and a global pharmaceutical acquirer, reached the same conclusion, that scaled women’s health businesses warrant multibillion-dollar commitments. A deeper and more varied buyer base means more paths to exit, which strengthens the case for investing in women's health.
Early-stage players in contraception, fertility and vaginal health in the Amboy St portfolio include:
Contraline (Series B) — Developing new male contraceptives, including NES/T, a daily hormonal gel headed for Phase 3, and ADAM, a non-hormonal, long-acting hydrogel implant
Granata Bio (Series A) — Fertility-focused biopharma building a pipeline of IVF medications to expand access and choice for fertility patients
Evvy (Series B) — At-home vaginal microbiome testing and personalized care, now expanding into fertility and IVF diagnostics
We look forward to keeping you updated as we invest in the $1T women's health and sexual health space.


